- Open
- 1.63
- High
- 1.65
- Low
- 1.62
- Close
- 1.63
- Change
- -0.06 (-3.61%)
- Volume
- 3,359,248
| 13 Jul 2026 | 07:00:11 | Mid-Year Operational and Corporate Summary |
| 29 Jun 2026 | 12:02:22 | Result of AGM |
| 22 Jun 2026 | 07:00:11 | Participation at BIO International Convention 2026 |
| 17 Jun 2026 | 07:00:06 | Company to present at Animal Longevity Summit 2026 |
| 4 Jun 2026 | 07:00:04 | Notice of AGM |
| 13 May 2026 | Annual financial statements 2025 | |
| 7 May 2025 | Annual financial statements 2024 | |
| 7 May 2024 | Audited Financial Statements Year Ended 2023 |
Genflow Biosciences plc develops gene therapies aimed at extending healthspan and addressing age-related conditions in both humans and canines. The company operates through two main divisions: Human Health, focusing on conditions such as metabolic dysfunction and sarcopenia, and Animal Health, which includes clinical trials for age-related issues in dogs. Genflow utilizes a proprietary SIRT6 gene therapy platform and has transitioned to LNP/mRNA delivery technologies to enhance treatment efficacy. The company is based in the United Kingdom and engages in research and development activities supported by grants and partnerships.
| 13 Jul 2026 | 07:00:11 | Mid-Year Operational and Corporate Summary |
| 29 Jun 2026 | 12:02:22 | Result of AGM |
| 22 Jun 2026 | 07:00:11 | Participation at BIO International Convention 2026 |
| 17 Jun 2026 | 07:00:06 | Company to present at Animal Longevity Summit 2026 |
| 4 Jun 2026 | 07:00:04 | Notice of AGM |
| 13 May 2026 | Annual financial statements 2025 | |
| 7 May 2025 | Annual financial statements 2024 | |
| 7 May 2024 | Audited Financial Statements Year Ended 2023 |
Genflow Biosciences plc develops gene therapies aimed at extending healthspan and addressing age-related conditions in both humans and canines. The company operates through two main divisions: Human Health, focusing on conditions such as metabolic dysfunction and sarcopenia, and Animal Health, which includes clinical trials for age-related issues in dogs. Genflow utilizes a proprietary SIRT6 gene therapy platform and has transitioned to LNP/mRNA delivery technologies to enhance treatment efficacy. The company is based in the United Kingdom and engages in research and development activities supported by grants and partnerships.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £319m | +0.4% | |
| £311m | -0.2% | |
| £90m | +0.2% | |
| £16m | -0.4% | |
| £11m | +0.0% | |
GENFGenflow Biosciences PLC | £9m | +1.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £319m | +0.4% | |
| £311m | -0.2% | |
| £90m | +0.2% | |
| £16m | -0.4% | |
| £11m | +0.0% | |
GENFGenflow Biosciences PLC | £9m | +1.0% |
